Contract Services Methods Development
Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion Transaction projected to ...
January 28, 2022 | News
InnoBation Bio, led by Seung-gu Kim (CEO), is a biopharmaceutical company specializing in the development of biomarkers, Chimeric Antigen Receptor (CAR) T ...
January 26, 2022 | News
The industry-leading automatic parenteral filling line features multiple filling modules and a built-in lyophilizer to fill vials, syringes, and ...
January 24, 2022 | News
On January 19, 2022, GenScript ProBio broke ground for the construction of its newest plasmid and viral vector manufacturing facility, a 34,000-square...
January 21, 2022 | News
Important milestone reached for the new site Additional filling capacities for early-stage clinical development First customer audits already completed...
January 20, 2022 | News
WuXi Biologics a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by&n...
January 18, 2022 | News
During the main track presentation today, John Rim, President and CEO of Samsung Biologics, addressed the company's vision for 2022 and business goals...
January 13, 2022 | News
Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufac...
January 07, 2022 | News
On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenS...
December 08, 2021 | News
Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnology company focused on advancing its proprietary nucleic acid i...
November 24, 2021 | News
Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production Increases up to 60 million vials...
November 01, 2021 | News
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed a remote G...
October 28, 2021 | News
Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. Q3'21 operating profit of KRW 167.4 billion increased 196% compa...
October 27, 2021 | News
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel bi...
October 25, 2021 | News
Most Read
Bio Jobs
News